Zusammenfassung
Systemische Amyloidosen sind seltene Erkrankungen, die im fortgeschrittenem Stadium zu irreversiblen Organschäden (am häufigsten Dialyse und/oder plötzlichem Herztod) führen. Für die systemische AL-Amyloidose wird eine Häufigkeit von 10–15 Neudiagnosen pro Jahr pro eine Million Einwohner in Industrienationen angegeben. Die aktuelle Nomenklatur gliedert die Amyloidosen nach ihrem jeweiligen Vorläuferprotein.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Dittrich T, Benner A (2019) Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica 104(7):1451–1459
Dittrich T, Bochtler T (2017) AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood 130(5):632–642
Kimmich C, Schönland S (2017) Amyloid in bone marrow smears in systemic light-chain amyloidosis. Amyloid 24(1):52–59
Lavatelli F, Merlini G (2018) Proteomics with mass spectrometry imaging: beyond amyloid typing. Proteomics 18(7):1700353
Merlini G, Dispenzieri A (2018) Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers 4(1):38
Nativi-Nicolau J, Maurer MS (2018) Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol 33(5):571–579
Palladini G, Dispenzieri A (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30(36):4541–4549
Palladini G, Hegenbart U (2014) A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124(15):2325–2332
Schönland SO, Hegenbart U (2012) Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 119(2):488–493
Sipe JD, Benson MD (2016) Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 23(4):209–213
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Hegenbart, U., Schönland, S. (2020). Leichtketten (AL-) Amyloidose. In: Jäger, D., Zeier, M. (eds) Onko-Nephrologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-59911-2_8
Download citation
DOI: https://doi.org/10.1007/978-3-662-59911-2_8
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-59910-5
Online ISBN: 978-3-662-59911-2
eBook Packages: Medicine (German Language)